Brad H Nelson
Brad H Nelson
Director, Deeley Research Centre, BC Cancer Agency
Verified email at
TitleCited byYear
IL-2, regulatory T cells, and tolerance
BH Nelson
The Journal of Immunology 172 (7), 3983-3988, 2004
Biology of the interleukin-2 receptor
BH Nelson, DM Willerford
Advances in immunology 70, 1-81, 1998
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
SD Brown, RL Warren, EA Gibb, SD Martin, JJ Spinelli, BH Nelson, ...
Genome research 24 (5), 743-750, 2014
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
DD Bowtell, S Bhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ...
Nature reviews Cancer 15 (11), 668-679, 2015
Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing
JD Freeman, RL Warren, JR Webb, BH Nelson, RA Holt
Genome research 19 (10), 1817-1824, 2009
The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature
RJ deLeeuw, SE Kost, JA Kakal, BH Nelson
Clinical Cancer Research 18 (11), 3022-3029, 2012
Cytoplasmic domains of the interleukin-2 receptor β and γ chains mediate the signal for T-cell proliferation
BH Nelson, JD Lord, PD Greenberg
Nature 369 (6478), 333-336, 1994
CD20+ B cells: the other tumor-infiltrating lymphocytes
BH Nelson
The Journal of Immunology 185 (9), 4977-4982, 2010
New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway
H Gu, H Maeda, JJ Moon, JD Lord, M Yoakim, BH Nelson, BG Neel
Molecular and cellular biology 20 (19), 7109, 2000
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
NR West, K Milne, PT Truong, N Macpherson, BH Nelson, PH Watson
Breast cancer research 13 (6), R126, 2011
The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5
JD Lord, BC McIntosh, PD Greenberg, BH Nelson
The Journal of Immunology 164 (5), 2533-2541, 2000
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors
K Milne, M Kbel, SE Kalloger, RO Barnes, D Gao, CB Gilks, PH Watson, ...
PloS one 4 (7), 2009
CD20+ tumor-infiltrating lymphocytes have an atypical CD27− memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer
JS Nielsen, RA Sahota, K Milne, SE Kost, NJ Nesslinger, PH Watson, ...
Clinical cancer research 18 (12), 3281-3292, 2012
The impact of T‐cell immunity on ovarian cancer outcomes
BH Nelson
Immunological reviews 222 (1), 101-116, 2008
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer
JR Webb, K Milne, P Watson, RJ DeLeeuw, BH Nelson
Clinical cancer research 20 (2), 434-444, 2014
FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6-dependent mechanism
SF De Mattos, A Essafi, I Soeiro, AM Pietersen, KU Birkenkamp, ...
Molecular and cellular biology 24 (22), 10058-10071, 2004
Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
NR West, SE Kost, SD Martin, K Milne, BH Nelson, PH Watson
British journal of cancer 108 (1), 155-162, 2013
Standard treatments induce antigen-specific immune responses in prostate cancer
NJ Nesslinger, RA Sahota, B Stone, K Johnson, N Chima, C King, ...
Clinical Cancer Research 13 (5), 1493-1502, 2007
A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens
H Pere, Y Montier, J Bayry, F Quintin-Colonna, N Merillon, E Dransart, ...
Blood, The Journal of the American Society of Hematology 118 (18), 4853-4862, 2011
Defining the critical hurdles in cancer immunotherapy
BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ...
Journal of translational medicine 9 (1), 214, 2011
The system can't perform the operation now. Try again later.
Articles 1–20